Barbra Sasu - Allogene Therapeutics Chief Scientific Officer
| ALLO Stock | USD 1.63 0.06 3.55% |
Executive
Ms. Barbra Sasu, Ph.D., serves as Chief Scientific Officer of the Company. Barbra joined Allogene as Chief Scientific Officer in April 2018 when the company acquired the allogeneic cell therapy assets from Pfizer. Barbra received a Ph.D. from the Paterson Institute for Cancer Research in Manchester, UK, in the laboratory of T. Michael Dexter, FRS. She conducted postdoctoral research at Harvard Medical School in the laboratory of T. Keith Blackwell, M.D., Ph.D. Barbra joined Amgen in 2001 to work on normal and malignant hematology initially and later expanded her focus to include immuneoncology with an emphasis on T cell redirective therapies, specifically BiTE molecules. In 2013, she joined Pfizer to become involved with large molecule immunooncology including the Pfizer T cell redirection programs and led diligence to look for a CAR T collaboration partner. This collaboration search resulted in the Cellectis partnership in 2014 and the collaboration with Servier for clinical execution of UCART19 and other preclinical assets.
| Address | 210 East Grand Avenue, South San Francisco, CA, United States, 94080 |
| Phone | 650 457 2700 |
| Web | https://www.allogene.com |
Allogene Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2701) % which means that it has lost $0.2701 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5513) %, meaning that it created substantial loss on money invested by shareholders. Allogene Therapeutics' management efficiency ratios could be used to measure how well Allogene Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 20th of March 2025, Return On Tangible Assets is likely to drop to -0.49. In addition to that, Return On Capital Employed is likely to drop to -0.56. At this time, Allogene Therapeutics' Total Assets are very stable compared to the past year. As of the 20th of March 2025, Non Current Assets Total is likely to grow to about 248.6 M, while Net Tangible Assets are likely to drop about 732.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Yuko JD | Sana Biotechnology | N/A | |
| Sunil PharmD | Annexon | N/A | |
| Deborah Palestrant | Relay Therapeutics | N/A | |
| Jeanne Gray | Relay Therapeutics | N/A | |
| Ryan Fischesser | Caribou Biosciences | N/A | |
| David MD | Iteos Therapeutics | N/A | |
| Julian Baker | Blueprint Medicines Corp | 58 | |
| Jim Watters | Relay Therapeutics | N/A | |
| Sravan Emany | Beam Therapeutics | 46 | |
| Amy Pooler | Sangamo Therapeutics | N/A | |
| Gregory Whitehead | Editas Medicine | N/A | |
| Brian JD | Relay Therapeutics | 51 | |
| Gary MD | Sana Biotechnology | N/A | |
| Linea Aspesi | Editas Medicine | 55 | |
| Peter Rahmer | Relay Therapeutics | N/A | |
| Sonja MD | Sana Biotechnology | 50 | |
| Morgan Conn | Century Therapeutics | 56 | |
| David Ojala | Sangamo Therapeutics | N/A | |
| Nathalie DuboisStringfellow | Sangamo Therapeutics | 62 | |
| JD Esq | Caribou Biosciences | 70 | |
| Caren Deardorf | Editas Medicine | 60 | |
Management Performance
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.27 |
Allogene Therapeutics Leadership Team
Elected by the shareholders, the Allogene Therapeutics' board of directors comprises two types of representatives: Allogene Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allogene. The board's role is to monitor Allogene Therapeutics' management team and ensure that shareholders' interests are well served. Allogene Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allogene Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Moore, Executive Officer | ||
| Rafael MD, Ex RD | ||
| Joshua Kazam, Co-Founder, Director | ||
| Geoffrey Parker, Executive CFO | ||
| FACS FACS, CoFounder Chairman | ||
| Susan Lundeen, Chief Officer | ||
| Veer Bhavnagri, G Officer | ||
| Earl Esq, General Officer | ||
| Christine Cassiano, Chief Officer | ||
| Benjamin Beneski, Senior Officer | ||
| Annie Yoshiyama, Corporate VP | ||
| Yinlin Chen, Senior Finance | ||
| MD FACS, CoFounder Chairman | ||
| Alison Moore, Chief Technical Officer | ||
| David JD, Secretary | ||
| Eric Schmidt, Chief Officer | ||
| Stephen Cheng, Chief Officer | ||
| Barbra Sasu, Chief Scientific Officer |
Allogene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allogene Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 165.46 M | ||||
| Shares Outstanding | 217.26 M | ||||
| Shares Owned By Insiders | 17.73 % | ||||
| Shares Owned By Institutions | 77.83 % | ||||
| Number Of Shares Shorted | 33.66 M | ||||
| Price To Earning | (3.30) X | ||||
| Price To Book | 0.87 X | ||||
| Price To Sales | 16,690 X |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.